This is educational information, not medical advice, and The Peptide University does not sell peptides, supplies, or supplements. Many compounds discussed here are sold as “research chemicals” and are not approved for human use outside of clinical trials. Laws vary by country, and nothing here is a recommendation to obtain or use anything. Talk to a qualified clinician about your own situation.
Tesamorelin is FDA-approved (as Egrifta, since 2010) for HIV-associated lipodystrophy — excess visceral fat in people with HIV. It's noted as the only FDA-approved peptide specifically for visceral fat reduction. Uses beyond that indication are off-label.
What it is
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Like CJC-1295 it works “upstream” — prompting the body's own GH release — but unlike most peptides discussed online, it has a documented clinical evidence base and an approved indication.
How it works
By acting on GHRH receptors, tesamorelin stimulates the pituitary to release growth hormone, which in turn raises IGF-1. In its approved use, this drives a reduction in visceral adipose tissue (the deep abdominal fat associated with metabolic risk).
Approved use & evidence
Tesamorelin is described as standing apart precisely because it has a documented clinical evidence base, an FDA-approved indication, and a well-understood mechanism. It was approved in 2010 (Egrifta) for HIV-associated lipodystrophy and is noted as the only FDA-approved peptide for visceral fat reduction. That's a much stronger footing than the research-chemical peptides elsewhere in this directory.
Safety
Because it raises GH and IGF-1, its effects and cautions track growth-hormone signaling — including potential joint aches, fluid retention, injection-site reactions, and effects on glucose metabolism that warrant monitoring. As an approved drug it comes with a defined label, contraindications, and monitoring guidance — another reason approved products differ from unsupervised use.
Regulatory status
FDA-approved for a specific indication (HIV-associated lipodystrophy); prescription-only. Any use outside that indication is off-label and should involve a clinician.
FAQ
QHow is it different from CJC-1295?
Both are GHRH-related and prompt GH release, but tesamorelin is an approved medication with trial evidence and a defined indication, whereas CJC-1295 is investigational and sold as a research chemical.
QIs it a weight-loss drug?
Its approval is specifically for reducing visceral fat in HIV-associated lipodystrophy — not general weight loss. Off-label use is a clinician conversation.
QDoes it raise IGF-1?
Yes — by stimulating GH release, it raises IGF-1, which is part of both its effect and its monitoring considerations.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Tesamorelin peptide: FDA-approved benefits, mechanism, who it's for (Perfect B)
- Growth hormone peptides guide: CJC-1295, ipamorelin & tesamorelin (Meto)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Questions & comments
No account, no login — leave a name or stay anonymous. Ask a question, add something the article missed, or answer someone else. Be kind and cite sources where you can.